Introduction {#S1}
============

Traumatic brain injury (TBI) represents one of the major causes of mortality and disability worldwide, with a global burden of approximately US\$ 400 billion annually (GBD 2016; [@B103]; [@B40]; [@B51]). Patients surviving the TBI usually suffer from various long-term neurological and neuropsychiatric sequelae, which include (but not limited to) neurodegenerative diseases ([@B37]) and sleep disturbances ([@B26]; [@B10]). Actually, TBI-induced neurodegenerative disease was first introduced in the 19th century in professional boxers who repeatedly suffered head trauma ([@B107]). From then on, accumulating evidence has suggested that TBI is a significant risk factor for a variety of neurodegenerative diseases such as Alzheimer's disease (AD) ([@B114]; [@B45]; [@B65]; [@B98]), Parkinson's disease (PD) ([@B53]; [@B73]), and amyotrophic lateral sclerosis (ALS) ([@B27]; [@B48]). Notably, sleep deprivation itself is an important predisposing factor for the development of neurodegenerative diseases ([@B18]; [@B152]; [@B32]).

Neurodegenerative diseases are declared a group of chronic diseases burdening the global aging society ([@B41]; [@B95]). Alzheimer's disease is considered the most common neurodegenerative disorders, followed by PD. In 2015, the former incurred worldwide losses totaling US\$ 818 billion, an increase of 35% over the previous five years ([@B47]; [@B108]; [@B6]; [@B181]). Although symptomatic and etiological treatments targeting patients with AD or PD may help alleviate some of the physical or mental symptoms of these incurable, age-related diseases, no treatment strategies have been proved sufficiently effective thus far ([@B6]; [@B90]; [@B111]; [@B120]). Another neurodegenerative disease, ALS, although relatively less frequent, has a high fatality rate and a median survival of only 14 months from the time of diagnosis ([@B102]). Therefore, considering the huge medical and social burden of neurodegenerative diseases and the increased incidence in patients with prior TBI, exploring the underlying mechanisms of causality between TBI and post-TBI neurodegenerative diseases is of great significance.

The neurovascular unit (NVU; [Figure 1](#F1){ref-type="fig"}) was originally introduced as a conceptual framework for cerebrovascular diseases, especially ischemic stroke, and has recently been identified as a key player in many other central nervous system (CNS) diseases, including TBI, whose primary and secondary pathologic processes can lead to persistent structural or metabolic abnormalities of the NVU ([@B190]; [@B100]; [@B125]). Recently, more and more lines of evidence have proved that NVU dysfunction is also related to neurodegenerative diseases ([@B23]). Thus, NVU dysfunction participates in both TBI and neurodegenerative diseases, and it may be a candidate mechanism underlying the TBI-induced neurodegenerative diseases. To understand the underlying mechanisms further, we propose the Neurovascular Unit Dysfunction (NVUD) Hypothesis, in which persistent NVU dysfunction accounts for the pathophysiological substrate and trigger condition for post-TBI neurodegeneration. In the present study, we elaborate on the functions of the components of the NVU and their significant roles in the pathophysiology of TBI. We also present scientific evidence supporting the involvement of NVU dysfunction in neurodegenerative disorders and attempt to summarize precise mechanisms linking acute TBI to chronic effects on neurodegeneration. Consequently, we suggest the reasonability of the NVUD Hypothesis and illuminate its value and limitations.

![Schematic illustration of the neurovascular unit. The neurovascular unit consists of neurons, neuroglia (astrocytes, microglia, and oligodendrocytes), vascular cells (pericytes, endothelial cells, and vascular smooth muscle cells) and the basal lamina matrix of brain vasculature.](fnins-14-00581-g001){#F1}

The Components of the NVU Play Critical Roles in the Homeostasis of the CNS {#S2}
===========================================================================

The paradigm of the NVU nowadays encompasses neurons, neuroglia (astrocytes, microglia, and oligodendrocytes), vascular cells (pericytes, endothelial cells, and vascular smooth muscle cells), and the basal lamina matrix of brain vasculature ([@B97]; [@B22]). Among these components, neurons may constitute the most pivotal cells for neurological function and have been studied by a great deal of previous work ([@B23]). In this section, we mainly focus on the components other than neurons, which also play critical roles in the homeostasis of the CNS and closely interact with neurons.

Glial Components in the NVU {#S2.SS1}
---------------------------

Brain-resident glial cells, which are comprised of astrocytes (astroglia), oligodendrocytes and microglia, exert various functions to maintain CNS homeostasis ([@B160]; [@B184]). Specifically, astrocytes, the most abundant brain-resident glial cells ([@B184]), stretch out their endfeet to the microvessels to regulate cerebral blood flow and form a functional barrier named glia limitans ([@B1]). Through the glia limitans, astrocytes separate neurons from the blood vessels, meninges and perivascular spaces ([@B159]). In addition to structural support for neurons, astrocytes also functionally favor neurons in a number of ways ([@B194]), including regulating the neurotransmitter glutamate ([@B138]; [@B3]; [@B196]), releasing neurotrophic factors and gliotransmitters ([@B185]; [@B85]; [@B125]), synthesizing glutamine, cholesterol, glutathione, and thrombospondin ([@B43]; [@B155]; [@B31]), converting glucose into lactate ([@B105]; [@B38]; [@B104]), and controlling water homeostasis and neuronal activation ([@B94]; [@B175]; [@B88]; [@B75]). Furthermore, the concentration of extracellular ions ([@B31]) and the glymphatic system ([@B77]) are regulated by astrocytes.

Microglia are immunocompetent cells in the CNS that are easily activated and have the function of recognizing and phagocytizing pathogens, debris and dead cells. They form the first line of defense system of the CNS and conduct phagocytosis-mediated cleanup during senescence or pathological processes ([@B69]). Conversely, microglia are also involved in the secretion of neurotoxins, such as nitric oxide and pro-inflammatory cytokines, which further deteriorate the cerebral microenvironment in pathological conditions ([@B62]).

Oligodendrocytes, another type of brain-resident glial cell, produce lipid-enriched myelin that wraps axons and accelerates nerve impulses ([@B128]). Taken together, glial cells can affect the outcome of patients with CNS disorders given the multifunctional roles of glial cells in the CNS.

Microvascular Components in the NVU {#S2.SS2}
-----------------------------------

Vascular cells involved in the NVU include pericytes, endothelial cells, and vascular smooth muscle cells. As vascular wall cells embedded in the microvascular basement membrane, pericytes are centrally positioned between endothelial cells, astrocytes and neurons ([@B164]). Pericytes are involved in signal transduction and communication with neighboring cells, through which they regulate blood--brain barrier (BBB) permeability, angiogenesis, neurotoxic metabolism and clearance, neuroinflammation, capillary hemodynamic response, and stem cell activity, demonstrating their vital role in the CNS during health and disease ([@B164]).

Similar to pericytes, endothelial cells are physiologically versatile cells that are involved in the maintenance of vascular homeostasis, regulation of cerebral vasoconstriction and vasodilatation, angiogenesis, and secretion of anti-coagulation factors. Expressing multiple substrate-specific transport systems, endothelial cells also play a vital role in controlling the exchange of CNS with peripheral substances and regulating the transport of ions and nutrients ([@B23]). Endothelial cells are highly connected through tight junctions (TJs) which restricts the paracellular diffusion of substances from blood to the CNS ([@B170]). These continuously interconnected endothelial cells, together with pericytes, the basal lamina matrix and the astrocytic end-foot processes, constitute the BBB ([@B118]). The integrity of the BBB is critical to the homeostasis and immunoprotection of the CNS ([@B118]). Of the microvascular components in the NVU, endothelial cells are the main component of the BBB ([@B23]) while pericytes primarily maintain the integrity of the BBB ([@B5]; [@B12]; [@B39]).

The Extracellular Matrix {#S2.SS3}
------------------------

The extracellular matrix (ECM) of the basal lamina functions as an anchor for the endothelium through cell-matrix interactions between laminin (or other matrix proteins) and the endothelial integrin receptors. Through these interactions, numerous intracellular signaling pathways can be stimulated ([@B70]; [@B167]). The TJs are thought to constitute the primary impediment of paracellular diffusion, therefore, given the involvement of matrix proteins in the regulation of expression of endothelial TJs, the basal lamina proteins are likely to maintain the diffusion as well ([@B168]). The ECM and TJs are fundamental to the permeability of the BBB and the degradation of these proteins under pathological circumstances can potently exacerbate BBB dysfunction ([@B132]). Additionally, matrix metalloproteinases (MMPs), particularly MMP-9, are capable of degrading the ECM and TJs, which enhances the permeability of the BBB and leads to vasogenic edema ([@B49]; [@B63]).

NVU Dysfunction in the Pathophysiology of TBI {#S3}
=============================================

While numerous causes of trauma exist, TBI is consistently related to both primary and secondary damage mechanisms ([@B99]). During TBI, mechanical force directly leads to instant damage, which includes neuronal damage and vascular disruption, followed by the secondary injury mediated by succeeding pathophysiological processes such as oxidative stress, neuroinflammation, BBB dysfunction, and apoptosis ([@B2]; [@B25]; [@B87]; [@B106]; [@B145]). All these primary and secondary pathologic processes contribute to the structural and/or metabolic abnormalities of the NVU, resulting in long-term neurological deficits in the patients ([@B190]; [@B125]).

Oxidative Stress {#S3.SS1}
----------------

Oxidative stress gives rise to progressive neuropathology during TBI and contributes primarily to secondary injury ([@B2]; [@B4]). Oxidative stress is considered physiological and biochemical stress or insult deriving mainly from reactive oxygen species (ROS) and reactive nitrogen species (RNS) ([@B2]). The enhanced production of ROS and RNS following TBI is due to excessive excitotoxicity and insufficient endogenous antioxidant systems. These reactive species result in increased oxidative stress and parallel the production of super-oxidized cellular and vascular structures, oxidized protein, cleaved DNA, and impaired mitochondrial electron transport chain, which can induce more ROS and RNS, thus triggering a vicious circle ([@B33]).

Oxidative stress and elevated toxic proteins can act on astrocytes to induce astrocyte-secreted pro-inflammatory factors, such as interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, and MMP-9, leading to the BBB compromise and neuroinflammation ([@B140]). Oxidative stress is a major contributor to endothelial impairment. Enriched with mitochondria for the normal performance of ATP-dependent active transporters, endothelial cells can thus malfunction under increased oxidative stress and impaired mitochondrial functions ([@B23]). Furthermore, oxidative stress and energy depletion induce the dysfunction of cellular ion channels that leads to the depolarization of neurons and the aggregation of excitatory neurotransmitters (e.g., glutamate), which further aggravate neuronal depolarization and the increase of toxic calcium levels ([@B177]). Moreover, enhanced oxidative stress and the subsequent biochemical cascade are adequate to induce early or late apoptosis, immediate cell necrosis and delayed neurodegeneration post TBI ([@B2]).

Neuroinflammation {#S3.SS2}
-----------------

Neuroinflammation is a hallmark of different CNS pathologies ([@B145]). Following the initial injury, the changed microenvironment and released intracellular components from damaged cells trigger the activation and recruitment of local glial cells ([@B34]; [@B61]; [@B147]). Both microglia and astrocytes react within 24 h and peak around day 3--7 post TBI ([@B50]; [@B42]; [@B162]). The activation and proliferation of glia release signaling factors and induce a robust, sterile immune reaction that consists of brain-resident and peripherally recruited inflammatory cells ([@B34]; [@B61]; [@B147]). In addition to danger signals released by damaged cells, mitochondrial stress, glutamate excitotoxicity, and vascular injury have also been identified as inflammatory triggers of neuroinflammation ([@B153]). This immune reaction is supposed to exert a neuroprotective role and promote wound healing, but it can become neurodestructive and aggravate neuronal damage under certain circumstances ([@B115]; [@B61]; [@B91]). For instance, resident glia and infiltrating immune cells up-regulate the expression of tumor necrosis factor (TNF)-α, IL-6, and IL-1β rapidly to cope with injury, among which, however, TNF-α is correlated with BBB disruption and brain edema, and can act together with IL-1β to drive astrocyte dysfunction and resultant glutamate excitotoxicity ([@B195]; [@B173]; [@B153]). Notably, many mediators activated after TBI may exhibit pleiotropic effects in a context-dependent manner. In this regard, the conceptual framework of NVU may also help understand the shifting profiles of TBI pathophysiology over time ([@B100]).

As the inflammatory response progresses, the glial progenitor cells around the damaged tissue form a glial scar, which isolates the injured areas and inhibits the spread of inflammatory cells ([@B158]; [@B86]; [@B21]; [@B124]; [@B159]). Nonetheless, the glial scar highly expresses inhibitory components for axonal regeneration and acts as both a physical and chemical barrier to axon elongation. The glial scar is therefore considered the main obstacle for axonal regeneration and the restoration of neuronal connectivity, which makes it a likely cause of the long-term sequelae in TBI patients ([@B174]; [@B76]; [@B36]; [@B147]).

Blood--Brain Barrier Dysfunction {#S3.SS3}
--------------------------------

The BBB functions as a key homeostatic site between the CNS and other major systems in the body ([@B192]). As the core feature of TBI, BBB dysfunction may indicate the severity of the injury as well as the length of recovery from TBI ([@B119]; [@B106]). The disruption of BBB integrity can result from the initial injury or arise secondarily from the succeeding pathological processes, including extensive inflammation, metabolic disturbances, and astrocytic dysfunction ([@B151]; [@B7]; [@B34]; [@B83]). Following the brain injury, several pro-inflammatory pathways such as the IL-1β/nuclear factor-κ-gene binding (NF-κB) signaling pathway ([@B126]; [@B163]) and the Janus kinase/signal transducers and activators of transcription 1 (JAK/STAT1) signaling pathway ([@B55]) have been demonstrated to induce the upregulation of MMPs and the consequential degradation of the ECM and TJs. Moreover, upregulated NF-κB, as a transcription factor, also induces the transcription of pro-inflammatory genes and enzymes, including intracellular adhesion molecule-1 (ICAM-1) and inducible nitric oxide synthase (iNOS; [@B92]). The former has been shown to increase BBB permeability through facilitating transendothelial leukocyte migration ([@B118]) while the latter has been identified to be excitotoxic and neurotoxic as well as activate MMPs via nitric oxide ([@B78]; [@B24]). In addition, neuroinflammation and energy depletion result in the impairments of ionic transport, transporters, and mitochondrial oxidative metabolism of endothelial cells, which all exacerbate the breakdown of the BBB ([@B121]). Moreover, the BBB compromise can, in turn, aggravate the inflammatory response due to the enhanced influx of serum elements, proinflammatory molecules, and infiltrating leukocytes. It can also lead to cerebral hemorrhage, brain edema, and hypoxia ([@B151]; [@B7]; [@B34]; [@B83]).

As described above, TJ-interconnected endothelial cells and pericytes are the main constituents that primarily contribute to the maintenance of the BBB ([@B5]; [@B12]; [@B39]; [@B23]). The impairment of crosstalk between them ultimately leads to BBB dysfunction after TBI onset ([@B15]). Astrocytes also hold a critical role in BBB function and cerebral water homeostasis ([@B20]) as astrocytic end-foot processes ensheathe the BBB and densely express perivascular aquaporin-4 (AQP4) channels ([@B101]; [@B165]). In addition, BBB permeability can be altered by astrocyte-derived factors ([@B112]). Moreover, other cell types involved in the NVU have also been shown to affect BBB homeostasis after TBI. For example, studies have indicated that oligodendrocyte precursor cells protect BBB against disruption via the transforming growth factor-β (TGF-β) signaling pathway ([@B144]). The activation, proliferation and phenotypic transformation of microglia indirectly have an impact on BBB function considering their involvement in the inflammatory response, especially the pro-inflammatory role (such as iNOS-expressing) of M1-like phenotype ([@B93]). These glial cells and microvascular cells have a functional interaction with each other in a paracrine manner ([@B2]). Therefore, the coordinated response of all components within the NVU is the determinant of BBB integrity ([@B100]).

Persistent NVU Abnormalities and Imaging/Serum/CSF Biomarkers {#S3.SS4}
-------------------------------------------------------------

Growing evidence has demonstrated these post-TBI NVU abnormalities may persist for months or years, especially in patients with a history of moderate-to-severe TBI ([@B65]; [@B98]). Reports regarding long-term brain changes after milder injuries have been mixed, and the results were often complicated by factors concerned with the number and severity/complications of injuries, genetic risk, and mental states and behavior ([@B65]; [@B98]). Diffuse axonal injury has been found in TBI of any severity and post-mortem studies reported widespread axonal pathology could continue for a sufficient length of time (weeks to months, even years) after mild-to-severe TBI in humans ([@B17]; [@B79], [@B80]; [@B148]; [@B99]). A continuum of microglia activation across a wide range of TBI conditions was also observed in animal models ([@B116]; [@B117]) and human autopsy (form different cause) ([@B52]; [@B79]), even up to 18 years after TBI, and this was related to the consistently ongoing white matter degeneration ([@B79]). However, the functional impact of these microglia is still an enigma, as controversy remains regarding whether they exhibit a pro-inflammatory or pro-regenerative phenotype ([@B131]; [@B79]; [@B139]; [@B142]; [@B166]). Evidence of prolonged reactive astrogliosis after even mild injuries was revealed by brain tissue from animal models ([@B156]) and humans ([@B54]; [@B150]; [@B166]) as well. Likewise, microvascular injury could be detected in the autopsy of long-term survivors from different types of TBI ([@B64]; [@B166]). These continued NVU dysfunctions could bring about chronic pathological processes such as oxidative stress, chronic neuroinflammation, and proteinopathy, which were also reported to be identified years post TBI and could, in turn, aggravate the NVU dysfunction ([@B81]; [@B153]; [@B98]). Although chronic oxidative stress has not yet been observed following a single mild human TBI, it appears that oxidative stress after concussion and its associated pathophysiological processes may worsen or prolong symptoms ([@B67]; [@B37]).

Currently, technological advances in clinical TBI neuroimaging make it possible to study NVU dysfunction and ensuing pathological processes *in vivo*, and findings by neuroimaging studies support the persistent abnormalities as well ([@B98]). For example, microglia activation and related chronic neuroinflammation in moderate to severe TBI survivors can be assessed up to 17 years after trauma by positron emission tomography (PET) imaging technology binding to translocator protein, which is expressed by mitochondria of activated microglia ([@B46]; [@B131]). Moreover, significant increased binding to translocator protein can be identified by PET technology decades after the history of repetitive mild TBI in retired athletes compared to healthy controls ([@B35]). Similarly, selective PET techniques with ligands for neurodegenerative proteins \[e.g., amyloid-β peptide (Aβ) and tau protein\] can image the deposition of proteinopathy, showing increased binding in moderate-severe TBI victims/retired athletes versus control cases ([@B68]; [@B9]; [@B141]). Advanced magnetic resonance imaging (MRI) modalities, such as diffusion tensor imaging (DTI, particularly in white matter pathology visualization), magnetic resonance spectroscopy (MRS, particularly in metabolic change assessment), susceptibility weight imaging (SWI, particularly in microscopic bleeding detection), and functional magnetic resonance imaging (fMRI, particularly in neurocognitive function examination) have emerged to allow the discovery of injury biomarkers and the detection of brain changes in patients with even mild TBI over time ([@B11]; [@B183]; [@B123]). Additionally, Single Photon Emission Computed Tomography (SPECT) scan also has significance, as being a promising tool for detecting regional functional changes in the brain of patients sustaining TBI ([@B11]).

Continued presence of some serum/plasma and CSF biomarkers is also able to persist many years post TBI, which depends on the type and extent of injury, thereby holding great promise for assessing the duration and degree of pathological processes ([@B180]; [@B98]). Proteins including Aβ, tau, α-synuclein, and nuclear transactive response DNA-binding protein 43 (TDP-43) are critically implicated in the pathogenesis of several different neurodegenerative diseases, and have been utilized as neurobiological markers to monitor neuronal damage following TBI, moreover, different marker binding fingerprints may function as predictors for a particular late-onset neurodegenerative disease ([@B180]). A growing body of literature data has suggested that neurofilament light in the blood and/or CSF also serves as a biomarker indicating neuronal injury after TBI ([@B146]; [@B14]). Besides, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, S100β, and neuron-specific enolase have shown immense value as reliable blood/CSF markers in predicting poor outcome and evaluating microstructural injuries undetected by computed tomography ([@B19]; [@B113]; [@B122]; [@B178]). Additionally, chronically elevated expression of serum cytokines may reflect chronic immune activation after TBI ([@B153]).

Patients With TBI Have Increased Susceptibility to Neurodegenerative Diseases {#S4}
=============================================================================

Accumulating evidence provides support for an association between the risk of developing neurodegenerative disease and a prior TBI event. Previous studies have reported an increased risk of AD among TBI victims ([@B135]; [@B45]). Similarly, 1.5--3.8 times higher incidence of PD has been reported in post-TBI cases ([@B53]; [@B73]). Traumatic brain injury, particularly of repeated TBI, is also considered a predisposing factor for ALS ([@B27]; [@B129]; [@B48]). Additionally, age at trauma has been suggested to be a determinant of the TBI victims' susceptibility to ALS ([@B143]; [@B129]). Notably, although vulnerability to neurodegenerative diseases has been indicated in patients with TBI of any severity, this increased susceptibility is more common in survivors sustaining moderate-to-severe TBI ([@B65]; [@B56]; [@B98]), and these patients have a 1.8-fold increase in neurodegenerative disease risk compared with those with mild TBI ([@B130]).

Unfortunately, mechanisms underlying this risk remain elusive thus far ([@B98]). Early after the initial injury, TBI can induce the production of pathological proteins, whose neurotoxicity contributes directly to persistent abnormalities of brain structure and function, with these proteinopathies lasting for months or years ([@B54]; [@B81], [@B79]; [@B64]; [@B180]). Intriguingly, post-TBI proteinopathies have similarities to multiple neurodegenerative diseases ([@B157]; [@B56]). For instance, pathological accumulation of Aβ and neurofibrillary tangles comprising hyperphosphorylated neuronal tau brings about the development of AD ([@B187]), similarly, α-synuclein is linked to PD ([@B84]). Furthermore, TDP-43 is considered the primary disease-related protein in ALS, and TDP-43 proteinopathy also features in other neurodegenerative disorders such as AD, PD, and Huntington's disease (HD; [@B82]). However, TDP-43 proteinopathy after TBI is more obscure and several controversial areas remain ([@B56]). The study by [@B179] addressed that brain trauma could boost ALS-related TDP-43 pathology, whereas the extent was modulated by ALS-related gene mutations, and the process was indicated to reversible and incapable of triggering ALS progression and neuronal vulnerability. Moreover, a single TBI does not appear to induce TDP-43 proteinopathy in humans ([@B82]). In addition to proteinopathies, chronic neuroinflammation and persistent oxidative stress may represent other candidates for the increased susceptibility. Neuroinflammation is a hallmark of CNS disorders, including TBI and neurodegenerative diseases ([@B66]; [@B139]; [@B145]). Oxidative stress gives rise to progressive neuropathology and contributes primarily to the secondary injury post TBI ([@B2]; [@B4]), concurrently being involved in the pathogenesis of neurodegenerative diseases ([@B37]).

Taken collectively, proteinopathies, persistent oxidative stress, and chronic neuroinflammation may be the pivotal intermediary pathological processes between early and delayed post-TBI changes ([@B98]). Herein we present that there is a pathological correlation between TBI and post-TBI neurodegenerative diseases, and we speculate it is the aforementioned persistent NVU dysfunction following TBI that accounts for the pathophysiological substrate and trigger condition for this pathological correlation. Readers seeking an in-depth discussion regarding the supporting evidence and internal mechanisms for this hypothesis should consult the section "Supporting Evidence and Precise Mechanisms." But before that, as we have elucidated the bond between NVU dysfunction and TBI pathophysiology, however, is NVU dysfunction involved in the pathophysiology of neurodegenerative diseases?

Is NVU Dysfunction Involved in the Pathophysiology of Neurodegenerative Diseases? {#S5}
=================================================================================

More and more lines of evidence favor the perspective that not only the neuronal degeneration and loss, but also aberrant neuroglia and vascular cells contribute to the pathogenesis of neurodegenerative diseases ([@B23]). In this section, we describe several roles of NVU components involved in the pathophysiology of AD, PD, and ALS.

Alzheimer's Disease {#S5.SS1}
-------------------

A growing number of studies from post-mortem brain tissue reveal the existence of neurovascular dysfunction in patients with AD, including brain capillary leakage, degeneration of BBB-related cells (e.g., endothelial cells and pericytes), brain infiltration of peripheral cells, abnormal angiogenesis and molecular changes ([@B165]).

Blood--Brain Barrier disruption is considered the key pathway of AD onset ([@B23]). This is firstly reflected in its impact on the aggregation of pathological protein. The dysfunction of NVU leads to aberrant cerebral blood flow regulation and impaired BBB transport, resulting in faulty Aβ clearance and increased Aβ production in soluble and fibrillary forms, which are the most neurotoxic and vasculotoxic forms ([@B13]). Accumulation of Aβ can subsequently induce oxidative stress, neuroinflammation and cell apoptosis, aggravating BBB impairment ([@B13]). Tau protein is associated with BBB compromise as well, as BBB dysfunction is in concert with the phenomenon that the major hippocampal blood vessels are surrounded by tau protein ([@B16]). In addition to pathological protein aggregation, AD is also pathologically characterized by chronic inflammation with the involvement of resident microglia and infiltrating peripheral immune cells ([@B66]). A dysfunctional BBB is convenient for migrating immune cells to infiltrate the CNS. In this context, when the requisite adhesion molecules are expressed, circulating leukocytes migrate into the brain parenchyma through activated brain endothelial cells and then interact with NVU components to further affect their structural integrity and function ([@B187]).

Parkinson's Disease {#S5.SS2}
-------------------

In PD pathogenesis, BBB dysfunction is not as important as it is in AD, but the effects of neuronal and glial cell damage are more crucial. Dopaminergic neuronal loss and Lewy bodies and Lowy neurites containing α-synuclein are the hallmarks of PD ([@B84]). Dopaminergic neurons are characterized as highly metabolic and thus have abundant amounts of mitochondria, the DNA of which is easily damaged by ROS and DNA repair can meanwhile be reduced in the absence of energy support ([@B96]; [@B57]). In addition, the metabolic process of dopamine itself will produce a large amount of accumulated ROS under pathological conditions ([@B23]). Therefore, oxidative stress and energy depletion can easily give rise to dopaminergic neuronal loss as well as α-synuclein aggregation, which further forms Lewy bodies and Lowy neurites.

Besides neuronal loss, glial components in the NVU also play a pivotal role in PD onset. Equipped with unmyelinated axons, dopaminergic neurons interact most closely with astrocytes ([@B136]; [@B137]). In normal physiological conditions, astrocytes provide both structural and functional support for dopaminergic neurons in multifactorial ways (see section "Glial Components in the NVU" for the detailed mechanisms) while dysfunctional astrocytes secrete various cytokines, chemokines, and excitotoxins, which contribute to a series of pathological processes ([@B140]; [@B194]). Furthermore, microglia--astrocyte interactions can further propel disease progression ([@B30]).

Amyotrophic Lateral Sclerosis {#S5.SS3}
-----------------------------

Amyotrophic lateral sclerosis is resulting from a complex combination of genetic predispositions and environmental insults. ALS-linked genes include *FUS*, *TARDBP* (the one encoding TDP-43), *SOD1*, *C9orf72*, among others ([@B154]). Based on the function of these genes, impaired cytoskeletal dynamics and axonal transport have emerged as a key role in ALS ([@B154]). Besides, dysfunctions of other NVU components are also involved in the pathogenesis of ALS. Both astrocytes and microglia have been argued to serve as central players in the pathogenesis. In the early stage of disease preceding the emergence of neuronal death and clinical symptoms, incompetent astrocytes due to astrodegeneration and astrocytic atrophy break the glutamate homeostasis and elicit glutamate excitotoxicity. Microglia are also induced to secrete neurotoxic factors, while in the later stage of disease, reactive astrogliosis and activated microglia may further promote neuronal damage and death ([@B172]). Additionally, the involvement of microvascular components in ALS pathology has also been suggested and microvascular compromise appears to precede the neuronal lesions and even the neuroinflammation ([@B60]).

The Neurovascular Unit Dysfunction Hypothesis and its Limitations {#S6}
=================================================================

Definition and Relational Reasoning {#S6.SS1}
-----------------------------------

The NVUD Hypothesis underscores the core role of NVU dysfunction in the development of post-TBI neurodegenerative diseases, which is concluded with relational reasoning from the following: (1) The NVU comprises neurons, neuroglial cells, vascular cells, and the basal lamina matrix of brain vasculature, playing critical roles in the homeostasis of the CNS, (2) all of the primary and secondary pathologic processes during TBI contribute to the persisting NVU dysfunction, including neuronal death, neuroglial dysfunction, and BBB compromise, (3) patients with TBI have an increased risk for developing neurodegenerative diseases, based on epidemiology and mutual pathological processes, and (4) NVU dysfunction is also involved in the pathophysiology of neurodegenerative diseases.

Additionally, we have mentioned in the previous sections that the persistent NVU abnormalities after TBI are related to the number and severity of injuries, and there is a dose--response relationship between TBI and later neurodegenerative disease. This similarity may further strengthen the reasonability of our assumption that continued NVU dysfunction serves as the pathophysiological substrate to trigger the development of post-TBI neurodegeneration.

Consistent with our relational inference, increasing supporting evidence obtained by animal models and human postmortem studies has suggested NVU dysfunction an important causative factor for post-TBI neurodegeneration ([Figure 2](#F2){ref-type="fig"}; [@B56]; [@B98]). These evidences also explain the induction of chronic neuroinflammation, persistent oxidative stress, and neurodegenerative protein aggregation after the initial injury.

![Schematic illustration of the Neurovascular Unit Dysfunction (NVUD) Hypothesis. During TBI, primary and secondary pathologic processes lead to persistent structural and/or functional abnormalities of the neurovascular unit, such as neuronal death, neuroglial dysfunction, and BBB compromise, which propel the progression of neurodegenerative diseases post TBI.](fnins-14-00581-g002){#F2}

Supporting Evidence and Precise Mechanisms {#S6.SS2}
------------------------------------------

Prolonged injured axons are considered a source of pathological proteins ([@B80]). Following TBI, the shear forces applied to the cytoskeleton result in damaged microstructure and impaired axonal transport ([@B109]; [@B166]), which is also involved in AD ([@B80]) and ALS ([@B154]) pathogenesis. Impaired axonal transport can lead to the co-accumulation of amyloid precursor protein (APP) and AAP-cleaving enzymes in axonal varicosities within just hours of trauma and thus, forming abundant Aβ in the varicosities ([@B29]; [@B171]; [@B28]; [@B169]). In the case where damaged axons eventually break down, these intraneuronal Aβ can aggregate in the parenchyma to form plaques ([@B29]; [@B80]). Shear forces also induce the dissociation of tau from microtubules, which is subsequently processed into a highly pathogenic tau form contributing to mitochondrial damage, neuronal apoptosis, and abnormal long-term potentiation ([@B89]; [@B166]). Besides, injured axons yield an extensive release of glutamate as well, coupled with cytokine stimulation, distorted glutamate receptor trafficking, and impaired glutamate clearance due to loss of astrocytic functional glutamate transporters, which together contribute to the dysregulation of glutamate homeostasis ([@B8]; [@B127]; [@B188]). This dysregulation is adequate to incur neuroexcitotoxicity as well as resultant oxidative stress and mitochondrial dysfunction post TBI ([@B33]; [@B2]), which are strictly implicated in the PD pathogenesis including dopaminergic neuronal loss and α-synuclein aggregation ([@B96]; [@B57]; [@B23]). Indeed, oxidative stress potentially plays a key role in protein carbonylation and pathological protein accumulation ([@B37]). Notably, TBI is suggested to form a transmissible self-propagating proteinopathy ([@B186]; [@B56]). Altogether, the possibility of persistent axonopathy and transmissible proteinopathy provide a potential mechanism for long-term and extensive neurodegeneration in the brain, thereby propelling progression of neurodegenerative diseases ([@B81], [@B80]; [@B186]; [@B56]).

Continued BBB dysfunction and neuroglial dysfunction following TBI are also implicated as triggers of post-TBI neurodegeneration, and the underlying mechanisms include, certainly, astrocyte dysfunction-induced impaired glutamate clearance as mentioned above. Perennial BBB alterations recruit brain-resident neuroglia and infiltrating leukocytes to form chronic neuroinflammation ([@B148]; [@B64]), which is also a pathological characteristic of neurodegenerative diseases ([@B66]; [@B145]). Similar to oxidative stress, neuroinflammation is indicated to elicit the abnormal accumulation of pathological proteins ([@B98]), which may further exacerbate vascular lesion as the perivascular location of proteinopathies has been observed in autopsies of TBI victims ([@B110]; [@B166]). The glymphatic system is a recently discovered brain-wide waste clearance pathway that utilizes astrocytic AQP4 channels to promote efficient elimination of interstitial solutes, including pathological proteins, from the CNS ([@B72]; [@B77]). In the acute phase following TBI, reactive astrogliosis is associated with alterations in AQP4 channel distribution and polarization, which are in line with the injury severity and persist for 14--28 days and 28 days in mild TBI and moderate TBI, respectively, resulting in decreased glymphatic influx and increased metabolic waste accumulation ([@B134]; [@B133]; [@B161]). Besides, decreased glymphatic function is also critically attributed to reactive astrogliosis-induced glial scars ([@B77]). Furthermore, the glymphatic system functions primarily during sleep and is largely suppressed during waking state, whereas sleep deprivation constitutes one of the most frequently reported chronic complications following TBI ([@B77]; [@B133]; [@B161]). As a result, the function of glymphatic pathway can be down to about 40% and maintained for at least 1 month after TBI ([@B71]; [@B77]). Therefore, both chronic impairment of BBB transport ([@B13]; [@B64]) and glymphatic pathway function ([@B71]; [@B161]) can induce impaired protein clearance, contributing to the succedent accumulation of neurotoxic and vasculotoxic proteins as well as the onset of post-TBI neurodegeneration.

Neurovascular Unit Dysfunction Hypothesis as a Promising Theoretical Basis for Treatment {#S6.SS3}
----------------------------------------------------------------------------------------

Neurovascular Unit Dysfunction abnormalities and ensuing pathological processes evolving over time have cast a spotlight on positive TBI interventions, which may be beneficial over an extended time frame ([@B131]). In the past, neuronal damage had been considered the main cause of functional impairment in brain injury or neurodegenerative diseases, and almost all the therapeutic strategies were targeted at repairing neuronal injury and rescuing neurons ([@B23]). However, in most cases, saving neurons alone seemed to be insufficient for treating brain injuries or diseases ([@B100]). We have previously reviewed the advance of a variety of stem cells in TBI treatment. Although some preclinical studies and small trials showed a good therapeutic effect, practical value of clinic application has not reached a general success ([@B193]). Analogously, stem cell therapies in other CNS diseases, including neurodegenerative diseases and stroke, have not generated substantial clinical improvements ([@B176]). The NVUD Hypothesis may provide new insights into the treatment strategies for TBI and potential prevention for later neurodegeneration, namely integrated restoration of all neural, neuroglial and vascular connectivity. Indeed, it is increasingly recognized that cell-cell crosstalk within the NVU components is absolutely required for remodeling and repair in acute brain injury and neurodegeneration ([@B100]). To date, several candidate agents have been found to promote the restoration of NVU integrity in TBI models, such as sonic hedgehog, and troxerutin cerebroprotein hydrolysate ([@B191]; [@B182]), more preclinical and clinical studies are warranted.

Limitations of NVUD Hypothesis {#S6.SS4}
------------------------------

There are some aspects that NVUD Hypothesis cannot explain. For instance, studies have revealed that cell-cell signaling within the NVU is crucial in the pathogenesis of HD and that TDP-43 pathology may feature in HD ([@B59]; [@B149]; [@B58]; [@B44]; [@B82]; [@B74]). However, the increased incidence of HD in TBI victims has been rarely reported. Moreover, despite universal occurred NVU dysfunction, only a subgroup of TBI victims develop late-onset neurodegenerative diseases, indicating other factors should be taken into consideration, such as genetic susceptibility (e.g., *APOE* genotyping) ([@B11]; [@B54]; [@B150]; [@B98]). Furthermore, aging not only increases the NVU's vulnerability to neurodegeneration, but also attenuates its self-repair capabilities ([@B23]; [@B176]). Thus, the crosstalk between NVUD Hypothesis and aging merits further explanation. The NVUD Hypothesis also needs further refinement. Although the NVU paradigm in this study focuses on the components surrounding the cerebral capillaries, critical roles of vascular components and perivascular nerve fibers connecting with larger blood vessels in CNS diseases have also been proposed ([@B189]). These groups of structures may need to be incorporated into an expanded NVUD paradigm, which will revise the NVUD Hypothesis.

Conclusion {#S7}
==========

In the present study, we propose the NVUD Hypothesis and discuss the reasonability. We also present its value as a promising theoretical basis for treatment and illustrate the limitations of this theory. The NVUD Hypothesis emphasizes that persistent NVU dysfunction functions as the pathophysiological substrate and trigger for late-onset neurodegeneration after TBI. Specifically, continued NVU abnormalities following TBI incur the chronic neuroinflammation, persistent oxidative stress, and neurodegenerative proteins aggregation, which in turn exacerbate NVU dysfunction and thus, forming a vicious circle and consequently leading to the progression of neurodegenerative diseases.
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A β

:   amyloid β peptide

AD

:   Alzheimer's disease

ALS

:   amyotrophic lateral sclerosis

AQP4

:   aquaporin-4

BBB

:   blood--brain barrier

CNS

:   central nervous system

DTI

:   diffusion tensor imaging

ECM

:   extracellular matrix
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HD

:   Huntington disease

HTT
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ICAM-1

:   intracellular adhesion molecule-1

IL

:   interleukin
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:   inducible nitric oxide synthase

JAK

:   Janus kinase

MCP

:   monocyte chemoattractant protein

MMP

:   matrix metalloprotein

MRS

:   magnetic resonance spectroscopy

MSNs

:   medium spiny neurons

NF κ B

:   nuclear factor- κ B

NVU

:   neurovascular unit

NVUD

:   Neurovascular Unit Dysfunction

PD

:   Parkinson's disease

PET

:   positron emission tomography

RNS

:   reactive nitrogen species

ROS

:   reactive oxygen species

SPECT

:   Single Photon Emission Computed Tomography

STAT1

:   signal transducers and activators of transcription 1 SWI susceptibility weight imaging

TBI

:   traumatic brain injury

TGF-β

:   transforming growth factor- β,TJ, tight junction

TNF

:   tumor necrosis factor.
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